Telo Genomics Closes First Tranche of Convertible Debentures Financing

Core Viewpoint - Telo Genomics Corp. has successfully closed the first tranche of a non-brokered private placement offering, raising gross proceeds of $840,000 through the issuance of secured convertible debentures [1][2]. Financing Details - The debentures carry an interest rate of 15% per annum, compounded quarterly, and will mature on December 15, 2026. Holders can convert the principal amount into common shares at a conversion price of $0.05 per share before maturity [2]. - In connection with the sale of the debentures, Telo Genomics issued a total of 16,800,000 detachable warrants, each exercisable at an exercise price of $0.08 per share until February 17, 2027 [3]. - The proceeds from the offering are intended for lab trials and general working capital, with cash finder's fees of $58,800 paid and 1,176,000 finder's warrants issued, also exercisable at $0.08 per share until February 17, 2028 [4]. Regulatory and Compliance - The offering is subject to conditions, including necessary approvals from the TSX Venture Exchange, and the securities issued will be subject to a hold period expiring on June 18, 2026, in accordance with Canadian securities laws [5]. Company Overview - Telo Genomics is a biotech company focused on developing diagnostic and prognostic tests through chromosomal telomere analysis, with applications in oncology and neurological diseases. The company emphasizes the advantages of liquid biopsies, which are less invasive and more replicable than traditional methods [6]. - The company's proprietary technology has been validated in over 160 peer-reviewed publications and 30 clinical studies involving more than 3,000 patients with various cancers and Alzheimer's disease. Its lead application, Telo-MM, aims to provide critical information for treating Multiple Myeloma [6].